News headlines about ProPhase Labs (NASDAQ:PRPH) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ProPhase Labs earned a news impact score of 0.17 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.4950353033483 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
PRPH stock opened at $2.96 on Monday. The stock has a market capitalization of $32.94, a PE ratio of 3.84 and a beta of 0.16. ProPhase Labs has a 1-year low of $1.78 and a 1-year high of $3.43.
WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact ProPhase Labs (PRPH) Stock Price” was originally reported by BBNS and is the property of of BBNS. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/02/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-prophase-labs-prph-stock-price/2003131.html.
ProPhase Labs Company Profile
ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.